Madrigal Pharmaceuticals (MDGL) PT Raised to $500 at Oppenheimer on Rezdiffra Patent
Tweet Send to a Friend
Oppenheimer analyst Jay Olson raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $500.00 (from $475.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
